237 related articles for article (PubMed ID: 29125981)
1. The clinical development of vaccines for HER2
Costa RLB; Soliman H; Czerniecki BJ
Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
3. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
4. HER2-Based Immunotherapy for Breast Cancer.
Cui N; Shi J; Yang C
Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
[TBL] [Abstract][Full Text] [Related]
5. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
6. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
Milani A; Sangiolo D; Montemurro F; Aglietta M; Valabrega G
Ann Oncol; 2013 Jul; 24(7):1740-1748. PubMed ID: 23585514
[TBL] [Abstract][Full Text] [Related]
7. Developing anti-HER2 vaccines: Breast cancer experience.
Al-Awadhi A; Lee Murray J; Ibrahim NK
Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
9. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.
Nocera NF; Lee MC; Czerniecki BJ
Future Oncol; 2017 Jul; 13(17):1459-1462. PubMed ID: 28766964
[No Abstract] [Full Text] [Related]
10. Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
Armstrong AC; Gilham DE
Breast Cancer Res; 2012 May; 14(3):106. PubMed ID: 22643384
[TBL] [Abstract][Full Text] [Related]
11. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
12. Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Breast Cancer.
Marmé F
Oncol Res Treat; 2016; 39(6):335-45. PubMed ID: 27260697
[TBL] [Abstract][Full Text] [Related]
14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
15. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
De La Cruz LM; Nocera NF; Czerniecki BJ
Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
[TBL] [Abstract][Full Text] [Related]
16. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
[TBL] [Abstract][Full Text] [Related]
17. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
Orlandi F; Guevara-Patiño JA; Merghoub T; Wolchok JD; Houghton AN; Gregor PD
Vaccine; 2011 May; 29(20):3646-54. PubMed ID: 21435405
[TBL] [Abstract][Full Text] [Related]
18. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Vaccines: Disappointing or Promising?
Zhu SY; Yu KD
Front Immunol; 2022; 13():828386. PubMed ID: 35154149
[TBL] [Abstract][Full Text] [Related]
20. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
Jackson DO; Trappey FA; Clifton GT; Vreeland TJ; Peace KM; Hale DF; Litton JK; Murray JL; Perez SA; Papamichail M; Mittendorf EA; Peoples GE
Clin Immunol; 2018 Oct; 195():28-35. PubMed ID: 30025819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]